Cargando…

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors

PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is a monogenic disorder characterized by high plasma levels of low-density lipoprotein cholesterol (LDL-C) since birth and a high risk of premature cardiovascular disease. The genetic defect is carried in only one allele in heterozygous FH (HeFH)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirillo, Angela, Catapano, Alberico L., Norata, Giuseppe D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Nonstatin Drugs (M. Vrablik, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549899/ https://www.ncbi.nlm.nih.gov/pubmed/34698927 http://dx.doi.org/10.1007/s11883-021-00972-x

Ejemplares similares

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

LOX-1, OxLDL, and Atherosclerosis
por: Pirillo, Angela, et al.
Publicado: (2013)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
por: Bonacina, Fabrizia, et al.
Publicado: (2021)

Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
por: Pirillo, Angela, et al.
Publicado: (2015)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges
por: Elbers, L.P.B., et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016)

Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?
por: Toledo-Ibelles, Paola, et al.
Publicado: (2018)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
por: Olmastroni, Elena, et al.
Publicado: (2022)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases
por: Pirillo, Angela, et al.
Publicado: (2013)

Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events
por: Magnoni, Marco, et al.
Publicado: (2022)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i12jgs0khlrtpcjpunifrbkeli